MPE Masterclass 2024 agenda

3 – 5 May 2024 – Madrid, Spain 

 

Friday, 3 May 2024
14:00 – 17:00 Participants check-in and registration
19:00 – 22:00 Welcome dinner at the hotel restaurant

Saturday, 4 May 2024
09:00 – 09:15 Welcome

Lise-lott Eriksson, President of MPE

 
09:15 – 10:30 Plenary session 1 –  Myeloma and AL amyloidosis treatment updates

Dr Albert Oriol, Head of the Clinical Research Unit, Institut Català d’Oncologia (ICO)

 
10:35 – 11:35 Plenary session 2 – Side effects and management of myeloma and AL amyloidosis treatment

Dr Charlotte Pawlyn, Haematologist and Clinician Scientist, Cancer Research UK

 
11:35 – 12.00 Coffee break   
12:00 – 13:15 Plenary session 3 – Real World Evidence (RWE)
  • Karen Facey, PhD CStat Hon MFPH, FIPRA Public Affairs, Senior Advisor – Health Technology Assessment
  • Dr Jelena Bila, Professor Dr sci med, Head of the Ward at Clinic of Hematology, University Clinical Center of Serbia
  • Martine Elias, Executive Director, Myeloma Canada
 
13:15 – 14:30 Morning session close and lunch break  
14:30 – 15:30 Breakout session 1 – Effective communication between the patient and the medical team (Shared decision-making)

Silene Ten Seldam, Research Assistant, MPE

Breakout session 2 – Addressing challenges and importance of the European Young Myeloma Patients Group
  • Ellen Watters, Myeloma Information Specialist, Myeloma UK
  • Pippa Foster, Director of Patient Services, Myeloma UK
  • Vincent Claus, Myeloma Patient, Belgium
15:30 – 16:00 Coffee break
 
16:00 – 17:00 Plenary Session 4 – Cross-border access to medicine and trials
  • Ananda Plate, Executive Director, Patvocates
  • Expert from EPF, TBD
17:00 – 18:00 Poster presentations and info stands
(15 mins poster introduction and 45 mins presentation)
Member programmes, success stories and MPE projects
20:00 – 23:00 Offsite dinner

Sunday, 5 May 2024
09:00 – 09:15 Welcome
09:15 – 10:30 Plenary Session 5 – EU Health Technology Assessment Regulation
  • Valentina Strammiello, Director of Programmes, EPF project portfolio and represents EPF in HTA-related activities in the European Health Parliament initiative
  • Karen Facey, PhD CStat Hon MFPH, FIPRA Public Affairs, Senior Advisor – Health Technology Assessment
10:30 – 11:00 Coffee break 
11:00 – 11:30 Video screening – “Myeloma is our story”
11:30 – 12:45 Panel Discussion 1 – Supportive care for myeloma and AL amyloidosis patients
  • Surabhi Chaturvedi, Senior psychotherapist and team lead (Haemato-Oncology/ Transplant/ CAR-T) at King’s College Hospital NHS Foundation Trust
  • Orla McCourt, Clinical academic physiotherapist at University College London Hospitals NHS Foundation Trust (UCLH)
  • Nada Rotovnik Kozjek, PhD, MD, Head, Clinical Nutrition Unit, Institute of Oncology Ljubljana, Slovenia
  • Christine Skeet, Nurse Specialist, Eastbourne, England, United Kingdom
12:45 – 12:55 Clinical Trial Navigator launch

Solène Clavreul, PhD, Head of Medical Education and Scientific Engagement, MPE

12:55 – 13:00 Masterclass close
12:55 – 13:00 Farewell lunch